{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T14:59:54Z","timestamp":1773327594415,"version":"3.50.1"},"reference-count":24,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical and Biophysical Research Communications"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.bbrc.2025.152909","type":"journal-article","created":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T15:45:29Z","timestamp":1762011929000},"page":"152909","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["REV3L as a prognostic biomarker and therapeutic target in bladder urothelial carcinoma"],"prefix":"10.1016","volume":"790","author":[{"given":"Yangyang","family":"Pang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tiantian","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junji","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenyao","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbrc.2025.152909_bib1","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.bbrc.2025.152909_bib2","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.eururo.2020.03.055","article-title":"European Association of Urology Guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2020 Guidelines","volume":"79","author":"Witjes","year":"2021","journal-title":"Eur. Urol."},{"key":"10.1016\/j.bbrc.2025.152909_bib3","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"10.1016\/j.bbrc.2025.152909_bib4","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1038\/nrc2998","article-title":"DNA polymerases and cancer","volume":"11","author":"Lange","year":"2011","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.bbrc.2025.152909_bib5","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.3892\/or.2016.4549","article-title":"REV3L, the catalytic subunit of DNA polymerase \u03b6, is involved in the progression and chemoresistance of esophageal squamous cell carcinoma","volume":"35","author":"Zhu","year":"2016","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.bbrc.2025.152909_bib6","article-title":"REV3L, a promising target in regulating the chemosensitivity of cervical cancer cells","volume":"10","author":"Yang","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.bbrc.2025.152909_bib7","author":"Kong"},{"key":"10.1016\/j.bbrc.2025.152909_bib8","doi-asserted-by":"crossref","DOI":"10.1080\/08916934.2023.2234101","article-title":"DNA polymerase \u03b6 suppresses the radiosensitivity of glioma cells by regulating the PI3K\/AKT\/mTOR pathway","volume":"56","author":"Ding","year":"2023","journal-title":"Autoimmunity"},{"key":"10.1016\/j.bbrc.2025.152909_bib9","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.ctrv.2016.03.005","article-title":"Metabolic phenotype of bladder cancer","volume":"45","author":"Massari","year":"2016","journal-title":"Cancer Treat Rev."},{"key":"10.1016\/j.bbrc.2025.152909_bib10","doi-asserted-by":"crossref","first-page":"8829","DOI":"10.3390\/ijms21228829","article-title":"Clinical perspectives of ERCC1 in bladder cancer","volume":"21","author":"Koutsoukos","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bbrc.2025.152909_bib11","doi-asserted-by":"crossref","first-page":"982","DOI":"10.3390\/cancers15030982","article-title":"Glucose metabolism reprogramming in bladder cancer: hexokinase 2 (HK2) as Prognostic biomarker and target for bladder cancer therapy","volume":"15","author":"Afonso","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.bbrc.2025.152909_bib12","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.2147\/OTT.S152999","article-title":"Expression of pyruvate kinase M2 in human bladder cancer and its correlation with clinical parameters and prognosis","volume":"11","author":"Huang","year":"2018","journal-title":"OncoTargets Ther."},{"key":"10.1016\/j.bbrc.2025.152909_bib13","doi-asserted-by":"crossref","DOI":"10.1002\/cam4.70242","article-title":"PGK1 can affect the prognosis and development of bladder cancer","volume":"13","author":"Gao","year":"2024","journal-title":"Cancer Med."},{"key":"10.1016\/j.bbrc.2025.152909_bib14","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1474652","article-title":"Transcriptional signature of CD56bright NK cells predicts favourable prognosis in bladder cancer","volume":"15","author":"Khan","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bbrc.2025.152909_bib15","article-title":"The immune cell infiltration patterns and characterization Score in bladder cancer to identify prognosis","volume":"13","author":"Zhang","year":"2022","journal-title":"Front. Genet."},{"key":"10.1016\/j.bbrc.2025.152909_bib16","doi-asserted-by":"crossref","first-page":"3608","DOI":"10.1016\/j.molcel.2023.07.008","article-title":"Freedom to err: the expanding cellular functions of translesion DNA polymerases","volume":"83","author":"Paniagua","year":"2023","journal-title":"Mol. Cell"},{"key":"10.1016\/j.bbrc.2025.152909_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.omto.2023.100750","article-title":"Beyond ENO1, emerging roles and targeting strategies of other enolases in cancers","volume":"31","author":"Ni","year":"2023","journal-title":"Mol. Ther. Oncolytics"},{"key":"10.1016\/j.bbrc.2025.152909_bib18","doi-asserted-by":"crossref","DOI":"10.1515\/pp-2019-0003","article-title":"Resistance to anoikis in transcoelomic shedding: the role of glycolytic enzymes","volume":"4","author":"Wilson","year":"2019","journal-title":"Pleura Peritoneum"},{"key":"10.1016\/j.bbrc.2025.152909_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2024.216837","article-title":"The emerging role of lactate in tumor microenvironment and its clinical relevance","volume":"590","author":"Chen","year":"2024","journal-title":"Cancer Lett."},{"key":"10.1016\/j.bbrc.2025.152909_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2024.216649","article-title":"Crosstalk between metabolic remodeling and epigenetic reprogramming: a new perspective on pancreatic cancer","volume":"587","author":"Ren","year":"2024","journal-title":"Cancer Lett."},{"key":"10.1016\/j.bbrc.2025.152909_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2023.e22433","article-title":"Prediction of immune infiltration and prognosis for patients with urothelial bladder cancer based on the DNA damage repair-related genes signature","volume":"9","author":"Li","year":"2023","journal-title":"Heliyon"},{"key":"10.1016\/j.bbrc.2025.152909_bib22","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1038\/s41591-024-03324-9","article-title":"Oncolytic immunotherapy with nivolumab in muscle-invasive bladder cancer: a phase 1b trial","volume":"31","author":"Li","year":"2025","journal-title":"Nat. Med."},{"key":"10.1016\/j.bbrc.2025.152909_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.fct.2023.113774","article-title":"Circumventing drug resistance through a CK2-targeted combination via attenuating endogenous AhR-TLS-promoted genomic instability in human colorectal cancer cells","volume":"176","author":"Chen","year":"2023","journal-title":"Food Chem. Toxicol. Int. J. Publ. Br. Ind. Biol. Res. Assoc."},{"key":"10.1016\/j.bbrc.2025.152909_bib24","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.1037341","article-title":"Targeting glycolysis in non-small cell lung cancer: promises and challenges","volume":"13","author":"Xu","year":"2022","journal-title":"Front. Pharmacol."}],"container-title":["Biochemical and Biophysical Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X25016250?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X25016250?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T01:23:54Z","timestamp":1773278634000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006291X25016250"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":24,"alternative-id":["S0006291X25016250"],"URL":"https:\/\/doi.org\/10.1016\/j.bbrc.2025.152909","relation":{},"ISSN":["0006-291X"],"issn-type":[{"value":"0006-291X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"REV3L as a prognostic biomarker and therapeutic target in bladder urothelial carcinoma","name":"articletitle","label":"Article Title"},{"value":"Biochemical and Biophysical Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbrc.2025.152909","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"152909"}}